Evidence map›Paper›PMID 27868196›Full record

ArticleThe Journal of physiology2017

Differential regulation of blood flow-induced neovascularization and mural cell recruitment by vascular endothelial growth factor and angiopoietin signalling.

Oliver A Stone, James G Carter, P Charles Lin, Ewa Paleolog, Maria J C Machado, David O Bates

Open access · hybridAbstract read
In one paragraph

Article in The Journal of physiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. A step closer to improving cardiac homing of adipose-derived mesenchymal stem cells.American journal of physiology. Heart and circulatory physiology · 2019
    Article
  6. Article
  7. Review
  8. Article
  9. When angiogenesis is not good enough.The Journal of physiology · 2017
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Oliver A StoneMicrovascular Research Laboratories, Bristol Heart Institute, School of Physiology and Pharmacology, University of Bristol, Bristol, UK.
James G CarterMicrovascular Research Laboratories, Bristol Heart Institute, School of Physiology and Pharmacology, University of Bristol, Bristol, UK.ORCID 0000-0003-1860-9677
P Charles LinCenter for Cancer Research, National Institute of Cancer, Frederick, MD, 2170, USA.
Ewa PaleologKennedy Institute of Rheumatology, University of Oxford, 65 Aspenlea Road, Hammersmith, London, UK.
Maria J C MachadoMicrovascular Research Laboratories, Bristol Heart Institute, School of Physiology and Pharmacology, University of Bristol, Bristol, UK.ORCID 0000-0002-2729-4809
David O BatesMicrovascular Research Laboratories, Bristol Heart Institute, School of Physiology and Pharmacology, University of Bristol, Bristol, UK.ORCID 0000-0003-4850-2360
University of Bristol · GBUniversity of Nottingham · GBFrederick National Laboratory for Cancer Research · USHammersmith Hospital · GB

Funding

Vascular Biology SectionZIABC011390 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LIN, PENGNIAN · 2011 to 2020
$15.4M
British Heart Foundation BS/06/005British Heart Foundation FS/06/038British Heart Foundation PG/11/67/29067Medical Research Council MR/K013157/1
6 · The paper itself

Abstract

key pointsCombining nitric oxide (NO)-mediated increased blood flow with angiopoietin-1-Tie2 receptor signalling induces arteriolargenesis - the formation of arterioles from capillaries - in a model of physiological angiogenesis. This NO-Tie-mediated arteriolargenesis requires endogenous vascular endothelial growth factor (VEGF) signalling. Inhibition of VEGF signalling increases pericyte coverage in microvessels. Together these findings indicate that generation of functional neovasculature requires close titration of NO-Tie2 signalling and localized VEGF induction, suggesting that the use of exogenous VEGF expression as a therapeutic for neovascularization may not be successful. ABSTRACT: Signalling through vascular endothelial growth factor (VEGF) receptors and the tyrosine kinase with IgG and EGF domains-2 (Tie2) receptor by angiopoietins is required in combination with blood flow for the formation of a functional vascular network. We tested the hypothesis that VEGF and angiopoietin-1 (Ang1) contribute differentially to neovascularization induced by nitric oxide (NO)-mediated vasodilatation, by comparing the phenotype of new microvessels in the mesentery during induction of vascular remodelling by over-expression of endothelial nitric oxide synthase in the fat pad of the adult rat mesentery during inhibition of angiopoietin signalling with soluble Tie2 (sTie2) and VEGF signalling with soluble Fms-like tyrosine kinase receptor-1 (sFlt1). We found that NO-mediated angiogenesis was blocked by inhibition of VEGF with sFlt1 (from 881 ± 98% increase in functional vessel area to 279 ± 72%) and by inhibition of angiopoietin with sTie2 (to 337 ± 67%). Exogenous angiopoietin-1 was required to induce arteriolargenesis (8.6 ± 1.3% of vessels with recruitment of vascular smooth muscle cells; VSMCs) in the presence of enhanced flow. sTie2 and sFlt1 both inhibited VSMC recruitment (both 0%), and VEGF inhibition increased pericyte recruitment to newly formed vessels (from 27 ± 2 to 54 ± 3% pericyte ensheathment). We demonstrate that a fine balance of VEGF and angiopoietin signalling is required for the formation of a functional vascular network. Endogenous VEGF signalling prevents excess neovessel pericyte coverage, and is required for VSMC recruitment during increased nitric oxide-mediated vasodilatation and angiopoietin signalling (NO-Tie-mediated arteriogenesis). Therapeutic vascular remodelling paradigms may therefore require treatments that modulate blood flow to utilize endogenous VEGF, in combination with exogenous Ang1, for effective neovascularization.

Indexed as

Angiopoietin-1AnimalsMaleMesenteryNeovascularization, PhysiologicRats, WistarReceptor, TIE-2Regional Blood FlowSignal TransductionVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1Angiopoietin-1Flt1 protein, ratReceptor, TIE-2Vascular Endothelial Growth Factor Avascular endothelial growth factor A, ratVascular Endothelial Growth Factor Receptor-1angiogenesisangiopoitinarteriolargenesisneovascularisationVEGF

Identifiers

PMID27868196
PMCPMC5330904
OpenAlexW2742787123

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.